Vigil Neuroscience (NASDAQ:VIGL) Lowered to "Neutral" Rating by HC Wainwright

HC Wainwright lowered shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) from a buy rating to a neutral rating in a report issued on Tuesday morning, MarketBeat.com reports. They currently have $8.00 price objective on the stock, down from their prior price objective of $14.00. HC Wainwright also issued estimates for Vigil Neuroscience's FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $0.63 EPS.

Several other equities analysts have also issued reports on VIGL. Jefferies Financial Group lowered Vigil Neuroscience to a "hold" rating in a research note on Thursday, May 22nd. JMP Securities reiterated a "market perform" rating on shares of Vigil Neuroscience in a research note on Thursday, May 22nd. William Blair cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Citigroup lowered shares of Vigil Neuroscience to a "market perform" rating in a research note on Thursday, May 22nd. Finally, Mizuho downgraded shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Ten analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $10.80.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock traded down $0.01 during mid-day trading on Tuesday, reaching $7.88. 849,129 shares of the company traded hands, compared to its average volume of 652,735. The company has a market capitalization of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a fifty-two week low of $1.31 and a fifty-two week high of $7.95. The firm's fifty day moving average is $2.67 and its two-hundred day moving average is $2.42.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. As a group, equities research analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

A number of institutional investors and hedge funds have recently made changes to their positions in VIGL. BVF Inc. IL grew its position in Vigil Neuroscience by 121.3% during the first quarter. BVF Inc. IL now owns 4,013,633 shares of the company's stock worth $7,144,000 after buying an additional 2,200,000 shares during the period. 683 Capital Management LLC grew its holdings in shares of Vigil Neuroscience by 24.3% in the 1st quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company's stock worth $3,097,000 after acquiring an additional 340,000 shares during the period. Aberdeen Group plc increased its stake in Vigil Neuroscience by 226.3% in the 1st quarter. Aberdeen Group plc now owns 1,724,520 shares of the company's stock valued at $3,070,000 after purchasing an additional 1,196,048 shares in the last quarter. Blair William & Co. IL raised its holdings in Vigil Neuroscience by 219.1% during the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company's stock worth $1,840,000 after purchasing an additional 709,677 shares during the last quarter. Finally, Ensign Peak Advisors Inc increased its position in shares of Vigil Neuroscience by 16.1% in the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company's stock valued at $1,195,000 after buying an additional 97,580 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.